AbbVie’s Botox patent lawsuit is ‘very unlikely to derail’ Revance’s rival launch: analysts

AbbVie’s Botox patent lawsuit is ‘very unlikely to derail’ Revance’s rival launch: analysts
esagonowsky
Mon, 10/11/2021 – 09:32